InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...
Fierce Pharma

After scrapped trial, InflaRx could tap partner to revive development of COVID drug in rare skin disorder

In turn, the company—which is broadly seeking to develop inflammatory drugs targeting the complement system—anticipates ...
TipRanks on MSN

InflaRx outlines data analyses of Phase 3 study for vilobelimab in PG

InflaRx (IFRX) outlined multiple data analyses of the Phase 3 study for vilobelimab in pyoderma gangrenosum, which was terminated earlier this ...
Nasdaq

InflaRx N.V. Showcases Promising Vilobelimab Data for Pyoderma Gangrenosum and Hidradenitis Suppurativa at AAD 2025 Annual Meeting

InflaRx N.V. has announced the presentation of data on vilobelimab, its anti-inflammatory therapeutic targeting the complement system, at the 2025 American Academy of Dermatology Annual Meeting. The ...
Pharmabiz

AbbVie, Eisai receives approval for additional indication of Humira to treat pyoderma gangrenosum

AbbVie GK and Eisai Co, Ltd announced an approval of additional indication of Humira, a fully human anti-TNFa monoclonal antibody, for the treatment of pyoderma gangrenosum (PG). Humira was granted ...
Healio

First patient dosed in phase 3 vilobelimab trial for pyoderma gangrenosum

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Ulcerative pyoderma gangrenosum is a rare disease with ...

InflaRx N.V.: InflaRx Provides Update on Phase 3 Data Analyses for Vilobelimab in Pyoderma Gangrenosum

While the Phase 3 trial of vilobelimab in ulcerative pyoderma gangrenosum (PG) was terminated earlier this year due to ...